A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations

Launched by VERTEX PHARMACEUTICALS INCORPORATED · May 30, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to study a medication called Povetacicept. The main goals are to understand how well different forms of Povetacicept work in the body and to check if various presentations of the drug are similar in how they affect people. Researchers will also monitor the safety of the medication and how well participants tolerate it.

To participate, you need to be a healthy adult between the ages of 18 and 65, with a body mass index (BMI) between 18 and 32 and a total body weight of more than 50 kg. There are certain health conditions that could exclude you from the trial, such as having a recent fever or receiving certain vaccines shortly before the study starts. If you join, you can expect to have regular check-ins with the research team to ensure your safety throughout the study. This trial is not yet recruiting participants, so there will be more information available soon for those interested in taking part.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), inclusive
• • A total body weight of more than (\>) 50 kg
• Key Exclusion Criteria:
• • History of febrile illness that has not fully resolved within 14 days before the dose of study drug.
• • Immunization with a live vaccine within 45 days before study drug administration or a non live vaccine within 14 days before study drug administration.
• • Other protocol defined Inclusion/Exclusion criteria may apply.